A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups
BackgroundPrimary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover,...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.696147/full |
id |
doaj-500e366c639d45f688f61bc4f369c0cd |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yuting Gao Li Wei Li Wei Seok Jin Kim Liang Wang Yingzhi He Yanfang Zheng Yanfang Zheng Luca Bertero Alessia Pellerino Paola Cassoni Luca Tamagnone Luca Tamagnone Prochazka Katharina Theresa Alexander Deutsch Huien Zhan Jing Lai Yao Wang Hua You |
spellingShingle |
Yuting Gao Li Wei Li Wei Seok Jin Kim Liang Wang Yingzhi He Yanfang Zheng Yanfang Zheng Luca Bertero Alessia Pellerino Paola Cassoni Luca Tamagnone Luca Tamagnone Prochazka Katharina Theresa Alexander Deutsch Huien Zhan Jing Lai Yao Wang Hua You A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups Frontiers in Oncology primary central nervous system lymphoma lactate dehydrogenase-to-lymphocyte ratio prognostic parameter Memorial Sloan Kettering Cancer Center (MSKCC) score neutrophil-to-lymphocyte ratio |
author_facet |
Yuting Gao Li Wei Li Wei Seok Jin Kim Liang Wang Yingzhi He Yanfang Zheng Yanfang Zheng Luca Bertero Alessia Pellerino Paola Cassoni Luca Tamagnone Luca Tamagnone Prochazka Katharina Theresa Alexander Deutsch Huien Zhan Jing Lai Yao Wang Hua You |
author_sort |
Yuting Gao |
title |
A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups |
title_short |
A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups |
title_full |
A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups |
title_fullStr |
A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups |
title_full_unstemmed |
A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups |
title_sort |
novel prognostic marker for primary cns lymphoma: lactate dehydrogenase-to-lymphocyte ratio improves stratification of patients within the low and intermediate mskcc risk groups |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-08-01 |
description |
BackgroundPrimary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNSL patients cannot be classified using the IELSG score. We thus aimed to create a novel, effective and feasible prognostic model for PCNSL.MethodsWe included 248 PCNSL patients diagnosed with PCNSL. Our primary endpoint was the overall survival (OS) and we used the receiver operating characteristic (ROC) analysis to determine the optimal prognostic cut-off value for LLR (lactate dehydrogenase-to-lymphocyte ratio), neutrophil-to-lymphocyte ratio (NLR) and derived neutrophil-to-lymphocyte ratio (dNLR). Variable associated with OS were evaluated by univariate and multivariate analyses. 124 out of 248 patients were randomly selected as the internal validation cohort.ResultsBy univariate analysis, an age >60 years, Eastern Cooperative Oncology Group performance status (ECOG PS) >1, treatment with radiotherapy alone, high-risk groups of Memorial Sloan Kettering Cancer Center (MSKCC) score, NLR >4.74, dNLR >3.29, and LLR >166.8 were significantly associated with a worse OS. By multivariate analysis, the MSKCC score and LLR were confirmed as independent prognostic parameters for poorer OS. OS, however, was not significantly different between low- and intermediate-risk groups according to the MSKCC score, while LLR proved to be prognostically relevant and was thus used to develop a novel, effective three-tier PCNSL scoring system. Of 124 patients, 84 patients with survival data and LLR data were successfully validated by newly established PCNSL LLR scoring system.ConclusionsIn the present study, we demonstrate that a high LLR represents an independent unfavorable prognostic parameter in PCNSL patients which can be integrated into an effective prognostic model. |
topic |
primary central nervous system lymphoma lactate dehydrogenase-to-lymphocyte ratio prognostic parameter Memorial Sloan Kettering Cancer Center (MSKCC) score neutrophil-to-lymphocyte ratio |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.696147/full |
work_keys_str_mv |
AT yutinggao anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT liwei anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT liwei anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT seokjinkim anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT liangwang anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT yingzhihe anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT yanfangzheng anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT yanfangzheng anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT lucabertero anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT alessiapellerino anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT paolacassoni anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT lucatamagnone anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT lucatamagnone anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT prochazkakatharinatheresa anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT alexanderdeutsch anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT huienzhan anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT jinglai anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT yaowang anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT huayou anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT yutinggao novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT liwei novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT liwei novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT seokjinkim novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT liangwang novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT yingzhihe novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT yanfangzheng novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT yanfangzheng novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT lucabertero novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT alessiapellerino novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT paolacassoni novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT lucatamagnone novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT lucatamagnone novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT prochazkakatharinatheresa novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT alexanderdeutsch novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT huienzhan novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT jinglai novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT yaowang novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT huayou novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups |
_version_ |
1721223105231192064 |
spelling |
doaj-500e366c639d45f688f61bc4f369c0cd2021-08-03T13:55:17ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-08-011110.3389/fonc.2021.696147696147A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk GroupsYuting Gao0Li Wei1Li Wei2Seok Jin Kim3Liang Wang4Yingzhi He5Yanfang Zheng6Yanfang Zheng7Luca Bertero8Alessia Pellerino9Paola Cassoni10Luca Tamagnone11Luca Tamagnone12Prochazka Katharina Theresa13Alexander Deutsch14Huien Zhan15Jing Lai16Yao Wang17Hua You18Department of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, ChinaDepartment of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, ChinaNHC Key Laboratory of Birth Defects and Reproductive Health, Chongqing Population and Family Planning Science and Technology Research Institute, Chongqing, ChinaDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South KoreaDepartment of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaDepartment of Hematology, ZhuJiang Hospital of Southern Medical University, Guangzhou, ChinaDepartment of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, ChinaDepartment of Oncology, ZhuJiang Hospital of Southern Medical University, Guangzhou, ChinaPathology Unit, Department of Medical Sciences, University of Turin, Torino, ItalyDepartment of Neuro-Oncology, University and City of Health and Science Hospital, Torino, ItalyPathology Unit, Department of Medical Sciences, University of Turin, Torino, ItalyUniversità Cattolica del Sacro Cuore, Department of Life Sciences and Public Health, Rome, Italy0Fondazione Policlinico Universitario “A. Gemelli”- IRCCS, Rome, Italy1Clinical Department of Hematology, Medical University of Graz, Graz, Austria1Clinical Department of Hematology, Medical University of Graz, Graz, Austria2Department of Hematology, The First Affiliated Hospital of Jinan University, Guangzhou, China2Department of Hematology, The First Affiliated Hospital of Jinan University, Guangzhou, ChinaDepartment of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, ChinaDepartment of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, ChinaBackgroundPrimary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNSL patients cannot be classified using the IELSG score. We thus aimed to create a novel, effective and feasible prognostic model for PCNSL.MethodsWe included 248 PCNSL patients diagnosed with PCNSL. Our primary endpoint was the overall survival (OS) and we used the receiver operating characteristic (ROC) analysis to determine the optimal prognostic cut-off value for LLR (lactate dehydrogenase-to-lymphocyte ratio), neutrophil-to-lymphocyte ratio (NLR) and derived neutrophil-to-lymphocyte ratio (dNLR). Variable associated with OS were evaluated by univariate and multivariate analyses. 124 out of 248 patients were randomly selected as the internal validation cohort.ResultsBy univariate analysis, an age >60 years, Eastern Cooperative Oncology Group performance status (ECOG PS) >1, treatment with radiotherapy alone, high-risk groups of Memorial Sloan Kettering Cancer Center (MSKCC) score, NLR >4.74, dNLR >3.29, and LLR >166.8 were significantly associated with a worse OS. By multivariate analysis, the MSKCC score and LLR were confirmed as independent prognostic parameters for poorer OS. OS, however, was not significantly different between low- and intermediate-risk groups according to the MSKCC score, while LLR proved to be prognostically relevant and was thus used to develop a novel, effective three-tier PCNSL scoring system. Of 124 patients, 84 patients with survival data and LLR data were successfully validated by newly established PCNSL LLR scoring system.ConclusionsIn the present study, we demonstrate that a high LLR represents an independent unfavorable prognostic parameter in PCNSL patients which can be integrated into an effective prognostic model.https://www.frontiersin.org/articles/10.3389/fonc.2021.696147/fullprimary central nervous system lymphomalactate dehydrogenase-to-lymphocyte ratioprognostic parameterMemorial Sloan Kettering Cancer Center (MSKCC) scoreneutrophil-to-lymphocyte ratio |